CDX2 and colorectal carcinoma: In the same vein, by first analysing gene expression in 1,045 stage I–IV primary CRCs for CDX2 (n = 403) or IHC (n = 642) and in relation to 5-year RFS and OS, a study performed by Bruun et al. showed no significant association (p = 0.91) between the absence of CDX2 and the RFS rate in a cohort of 422 CRC-II patients of which 49 were characterised as CDX2-negative.